BJMO - volume 19, issue 1, january 2025
C. Fontaine MD, J. Collignon MD, P. Debruyne MD, PhD, L. Duck MD, E. Everaert MD, T. Feys MBA, MSc, C. Langenaeken MD, F. Lebrun MD, J. Mebis MD, E. Naert MD, P. Van Landuyt PharmD, S. Wuyts PharmD, C. van Marcke de Lummen MD, PhD, F. Vanryckeghem MD, V. Verschaeve MD, J. Klaskersky MD, PhD
Nausea and vomiting continue to be some of the more dreaded side effects of anticancer therapy. While advances in the prophylaxis of chemotherapy induced nausea vomiting (CINV), and guidance from international cancer societies have yielded important benefits for cancer patients, there remains an important need to further improve patient care. To address the need for a better CINV prophylaxis, and to respond to the introduction of new potentially emetogenic anticancer agents and the publication of new clinical trial data with anti-emetic agents, several international oncological societies have recently updated their guidelines for the prevention of CINV. The objective of this paper was to translate these new international recommendations to a Belgian context.
(BELG J MED ONCOL 2025;19(1):15–26)
Read moreBJMO - volume 15, issue 6, october 2021
W. Lybaert MD, A. Demols MD, PhD, I. Dero MD, I. Borbath MD, PhD, J. Collignon MD
The annual Gastrointestinal Cancers Symposium was held from 15 till 17 January 2021 in a virtual format. During this meeting, evolving immunotherapy options were shown in the upper digestive tractus, already presented at ESMO 2020. Besides immunotherapy, also the total neoadjuvant treatment approach (TNT) in rectal cancer reached sufficient attention, changing our current standard of practice in 2021. Targeted therapies for different gastrointestinal (GI) tumour locations showed promising results, paving the way for more personalised medicine.
In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2021;15(6):331-9)
Read moreBJMO - volume 15, issue 3, may 2021
A. Iabkriman MD, J. Collignon MD, F.P. Duhoux MD, PhD
The phosphatidylinositol-3-kinases (PI3Ks) play a critical role in cellular metabolism and proliferation, as well as in the development of cancer. Several mutations in the genes coding for PI3Ks have been identified in a large proportion of tumours at different rates, depending on the tumour type. Therapies targeting PI3Ks have been developed in the last years and initially used in hematological malignancies. In medical oncology, a number of trials have tried to prove the efficacy of these compounds, but most of them have been confronted with very important toxicities and only a modest benefit in progression-free survival. Recent trials using more selective treatments have shown good efficacy with an acceptable toxicity profile. The aim of this article is to review the current knowledge about PI3K inhibitors, their potential use in medical oncology and their toxicities.
(BELG J MED ONCOL 2021;15(3):96-103)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
